 |
|
Elevated Serum Granulocyte Colony-Stimulating Factor Levels in Patients With Active Phase of Sweet Syndrome and Patients With Active Behçet Disease
Implication in Neutrophil Apoptosis Dysfunction
Tamihiro Kawakami, MD, PhD;
Syuichiro Ohashi, MD, PhD;
Yoko Kawa, PhD;
Hideto Takahama, MD, PhD;
Masaru Ito, MD, PhD;
Yoshinao Soma, MD, PhD;
Masako Mizoguchi, MD, PhD
Arch Dermatol. 2004;140:570-574.
ABSTRACT
| |
Background Sweet syndrome (SS), an acute inflammatory disease, has clinical and laboratory features similar to those of Behçet disease (BD). Serum levels of granulocyte colony-stimulating factor (G-CSF) are elevated in patients with SS, and exogenous administration of G-CSF has repeatedly been implicated in the causation of SS. Granulocyte colony-stimulating factor is a hematopoietic growth factor that regulates the production and differentiation of neutrophils.
Objectives To clarify the role of elevated serum G-CSF levels in patients with active SS and active BD compared with those with inactive SS or BD and healthy controls. To then analyze neutrophil apoptosis in the active state of SS and BD; and to also investigate the influence of autologous serum on neutrophil apoptosis.
Methods Serum G-CSF was examined in 5 patients with active SS, 7 with inactive SS, 7 with active BD, 9 with inactive BD, and 5 healthy controls by means of an enzyme immunoassay kit. We measured apoptotic cells in the neutrophil fraction of peripheral blood collections in patients with active diseases and controls by means of flow cytometry.
Results Serum G-CSF level was significantly higher in patients with active SS than in those with inactive SS. The difference in serum G-CSF levels among patients with active and inactive BD was also significant. Serum G-CSF level was significantly higher in patients with active SS than in those with active BD. Neutrophil apoptosis was significantly higher in patients with active SS than healthy controls. This increased apoptosis rate was also seen in patients with active BD. The increased rate of neutrophil apoptosis was significantly suppressed when the neutrophils were cultured for 18 hours in the presence of autologous active SS serum. Similarly, neutrophil apoptosis was suppressed in the presence of autologous serum in patients with active BD, but not significantly so.
Conclusions These findings indicate that increased production of G-CSF in patients with SS and BD may play an important role in the manifestation of these disorders. Given the suppression of neutrophil apoptosis in the active state in the presence of the influence of autologous serum, which includes elevated G-CSF level, we propose that serum G-CSF plays a significant role in the suppression of neutrophil apoptosis. Furthermore, G-CSF–induced suppression of neutrophil apoptosis appears to be deeply involved in the pathogenesis of SS and BD.
INTRODUCTION
Sweet syndrome (SS) has been described as a rare but distinct disorder, characterized by 4 clinical features: fever, neutrophilic leukocytosis, sudden onset of asymmetric erythematous, and often-painful skin lesions and dense dermal infiltrates of mature neutrophils without signs of vasculitis. Behçet disease (BD) demonstrates symptoms similar to those of SS, although the incidence and clinical courses of these 2 disorders are different. Peripheral neutrophilia, enhanced neutrophil activity, and dense dermal infiltration of cutaneous lesions have also been noted in both disorders. Neutrophils may play an important role in the pathogenesis of these 2 diseases, as neutrophils are increased in blood and skin lesions.1
Recent observations have led to the notion that particular cytokines such as granulocyte colony-stimulating factor (G-CSF) are primarily involved in the pathogenesis of SS.2 This theory has arisen from studies that have demonstrated elevation of serum G-CSF levels in comparison with other cytokines during acute exacerbation of the disease.3 The validity of this theory has been substantiated by several recently reported cases of exogenous G-CSF–induced SS.4-11 Therapy with G-CSF for granulopenia is known to induce SS.12 Furthermore, our group previously suggested that G-CSF is intensively involved in BD.13
Granulocyte colony-stimulating factor is a hematopoietic growth factor that increases the number of peripheral neutrophils and active mature neutrophils.14-15 In steady-state hematopoiesis, G-CSF regulates the level of neutrophils in bone marrow and blood and is critical for the survival of granulocytic cells. The factor strongly influences neutrophil function by stimulating production, activation, maturation, and chemotaxis of granulocytes.16 Philpott et al17 showed that G-CSF suppressed apoptosis in vivo in a CD34+ cell population and thereby prolonged their survival.
In the present study, we attempt to measure serum G-CSF concentrations in patients with SS and BD and to evaluate the significance of disease activity. We subsequently examine the abnormal neutrophil apoptosis mechanism attributed to neutrophils in the active state of SS or BD.
METHODS
CLINICAL INVESTIGATION
The medical records of patients coded with the diagnosis of SS or BD were reviewed in a dermatology practice that examines university-based patients. Twelve cases satisfied the diagnostic criteria for SS.18 Sixteen patients presented with BD, diagnosed according to the criteria proposed by the International Study Group for Behçet's Disease.19-20 All patients were further divided according to either active or inactive state of the disease. Both clinical and laboratory findings were used for the diagnosis of active and inactive SS or BD. Active state was defined by worsening of clinical SS symptoms at the time of study, and the presence of at least both major criteria (abrupt onset of tender erythematous plaque or nodules; dense neutrophilic infiltrate on biopsy) and 2 of the 4 minor criteria. According to these criteria, 5 of our patients with SS were defined as having active disease (2 men and 3 women; mean ± SD age, 39 ± 5 years) and the other 7 were defined as having inactive disease (3 men and 4 women; mean ± SD age, 46 ± 7 years). Pathergy test21 results were clinically positive in 1 (8%) of 12 patients with SS. Clinically, patients with BD with worsening of clinical symptoms at the time of study with at least 3 of the major findings (aphthous stomatitis; genital ulcers; anterior iridocyclitis or posterior vasculitis or panuveitis; cutaneous findings; pathergy test positivity21) were considered to be in the active stage of the disease. The criteria of the International Uveitis Study Group were used for diagnosis of uveitis.22 Seven patients had BD in the active stage (3 men and 4 women; mean ± SD age, 38 ± 10 years) and 9 patients in the inactive stage (4 men and 5 women; mean ± SD age, 44 ± 8 years). Five healthy volunteers (2 men and 3 women; mean ± SD age, 38 ± 11 years) were included in this study. All patients gave informed consent before the study. Treatment included colchicine, corticosteroids, potassium iodide, dapsone, and immunosuppressive agents, and it was based on the severity of systemic manifestations. Colchicine provided effective long-term suppression of chronic SS.23
DETECTION OF G-CSF IN BLOOD SERUM
Serum G-CSF levels were measured by enzyme immunoassay, as described by Motojima et al.24 Recombinant human G-CSF (rhG-CSF) was obtained (Kirin Brewery, Tokyo, Japan). Each sample and serial dilution of rhG-CSF, together with enzyme immunoassay buffer containing 2% polyethylene glycol, was added to a polyethylene tube coated with rabbit anti–rhG-CSF (IgG). These tubes were incubated for 2 hours, after which they were incubated with horseradish peroxidase–conjugated rabbit anti–rhG-GSF (Fab') solution for another 2 hours. Substrate reagent was added after washing. The reaction was stopped with 4N sulfuric acid after incubation for 1 hour in the dark, and the resulting optical density was measured at 492 nm. Detectable levels of G-CSF in this enzyme immunoassay were greater than 60 ng/mL in our samples.
ISOLATION OF NEUTROPHILS AND APOPTOSIS ANALYSIS
Heparinized peripheral blood from patients with active SS, patients with active BD, and healthy volunteers was individually layered on Ficoll-Hypaque (Pharmacia, Uppsala, Sweden) solution and centrifuged at 1250g for 40 minutes at 20°C. The plasma was collected and stored at –70°C. Mononuclear cell fractions were recovered from the cell band between the plasma and Ficoll-Hypaque solution. The resulting buffer coat was collected as the neutrophil-rich fraction, and neutrophils were purified by carrying out hypotonic lysis of erythrocytes.25 Neutrophil fractions (viability, >90%; purity, 99%) were used for the polarization assay. The neutrophil suspension was washed, filtered, and placed in Roswell Park Memorial Institute 1640 medium supplemented with 10% fetal calf serum (FCS) (GIBCO, Grand Island, NY) and 10nM HEPES buffer. Some of the culture was incubated in the presence of 20% autologous serum. All of the experiments were performed under endotoxin-free conditions.
Apoptosis was measured by flow cytometry according to a previously published procedure after 0, 3, 6, and 18 hours of incubation.26-27 After culturing, the cells were centrifuged and the pellets gently resuspended in 1.5 mL of a hypotonic solution of propidium iodide (50 µg/mL in 0.1% sodium citrate plus 0.1% Triton X-100; Sigma Chemical Co, St Louis, Mo). The tubes were placed in the dark overnight at 4°C. The propidium iodide fluorescence of individual nuclei was measured by flow cytometry by means of a standard fluorescence-activated cell sorter (FACScan; Becton-Dickinson, Mountain View, Calif). Nuclear debris was excluded by an appropriate threshold on forward scatter in the acquisition step, and apoptotic bodies were excluded with an emission less than 10 in the red fluorescence channels (FL-3) during the analysis step. The 2 thresholds were determined to quantify the apoptotic event in the neutrophil population and to exclude material derived from its fragmentation. Ten thousand events were acquired and analyzed. All measurements were performed at the same instrument setting by the same operator.
STATISTICAL ANALYSIS
The 2-tailed, unpaired t test was used to compare statistical differences between 2 groups. The level of significance was set at P <.05 in all cases.
RESULTS
MEASUREMENT OF G-CSF IN SERUM
The mean serum G-CSF concentration was significantly higher (P <.01) in patients with active SS (115.4 ± 33.2 pmol/L) vs patients with inactive SS (Figure 1). Patients with BD in the active stage had significantly (P = .002) higher serum G-CSF concentrations (34.1 ± 12.8 pmol/L) than patients with inactive BD (Figure 1). Serum G-CSF levels were significantly higher in patients with active SS vs those with active BD (P <.05). Furthermore, mean concentrations for G-CSF were significantly higher (for each, P <.01) among both active SS and active BD groups compared with healthy controls (2.0 ± 0.3 pmol/L) (Figure 1). These findings suggest that elevated G-CSF levels may be useful in better understanding the pathogenesis of SS and BD. The G-CSF seems to be implicated in exacerbating the symptoms in these 2 disease conditions.
|
|
|
|
Figure 1. Serum granulocyte colony-stimulating factor (G-CSF) levels in patients with active Sweet syndrome (SS), inactive SS, active Behçet disease (BD), and inactive BD and healthy controls.
|
|
|
RATE OF NEUTROPHIL APOPTOSIS
To evaluate neutrophil apoptosis in the active phase of the 2 diseases and healthy controls, apoptosis was assessed by the propidium iodide method, as previously described by Nicoletti et al.27 The percentage of apoptotic nuclei was examined by reduced DNA content due to fragmentation and enhanced chromatin condensation. Percentage of DNA fragmentation was evaluated by the flow cytometric method after 0, 3, 6, and 18 hours of incubation. The percentage of apoptotic nuclei in the neutrophils of patients with active disease was higher than that among healthy controls. This difference was significant at 18 hours between patients with SS and controls (P<.05; Figure 2) but did not reach significance among patients with BD vs controls (Figure 2).
|
|
|
|
Figure 2. Percentage of apoptotic nuclei (reduced DNA content due to fragmentation and enhanced chromatin condensation) in neutrophils from patients with active Sweet syndrome, patients with active Behçet disease, and healthy controls, augmented in cell culture. The percentage of apoptotic neutrophils in patients with active Sweet syndrome increased significantly after 18 hours of incubation compared with controls.
|
|
|
To better understand apoptosis of neutrophils in the active disease state, we incubated these cells in medium supplemented with 10% FCS and added 20% autologous serum. The solution was then analyzed by flow cytometry. Under these conditions, the rate of apoptosis of neutrophils in patients with active SS was significantly attenuated at 18 hours (P <.05; Figure 3). Autologous serum induced a marked reduction in the percentage of hypodiploid forms, which are characteristic of apoptotic nuclei, and there was a concomitant increase in the proportion of diploid nuclei. This indicates that autologous serum induces a remarkable inhibition of neutrophil apoptosis in patients with active SS.
|
|
|
|
Figure 3. Percentage of apoptotic nuclei in neutrophils from patients with active Sweet syndrome after neutrophils were suspended in RPMI 1640 supplemented with 10% fetal calf serum (FCS) (GIBCO, Grand Island, NY) or 10% FCS plus autologous serum incubated for 0, 3, 6, or 18 hours. Autologous serum treatment induced a marked reduction in the proportion of neutrophil apoptosis after incubation for 18 hours.
|
|
|
The same methods were applied to neutrophils from patients in the active stage of BD. All assays were performed with the use of culture medium supplemented with 10% FCS and 20% autologous serum. To analyze whether proteolytic fragments generated by the action of autologous serum could be involved in the stimulation of neutrophil apoptosis, cells were incubated in 10% FCS or 10% FCS plus BD autologous serum for 0, 3, 6, and 18 hours. There was a distinct attenuation of apoptosis among nuclei treated with autologous serum for 18 hours vs those that were not (Figure 4).
|
|
|
|
Figure 4. Percentage of apoptotic nuclei in neutrophils from patients with active Behçet disease after neutrophils were treated with 10% fetal calf serum (FCS) (GIBCO, Grand Island, NY) or 10% FCS plus autologous serum. Analysis of apoptosis by flow cytometry, performed after incubation for 3, 6, and 18 hours, reduced by autologous serum treatment.
|
|
|
COMMENT
The findings from this study demonstrated that G-CSF levels in peripheral blood are significantly higher in active SS and active BD vs the inactive stage. The G-CSF is a growth factor that promotes the production and maturation of myeloid cells and, in particular, the proliferation and differentiation of neutrophil progenitors both in vitro and in vivo.28 Treatment with G-CSF can exacerbate preexisting inflammatory conditions, presumably by stimulating neutrophil proliferation and activity at sites of chronic inflammation.10 High levels of G-CSF in active SS or BD seem to be a useful indicator of the activity level in these diseases. Consequently, we propose that G-CSF may induce the active phase of SS via stimulatory effects on the production and function of neutrophils. The molecular basis for enhanced neutrophil function in the active state is unknown. Elevated serum G-CSF levels suggest that the cytokine physiologic activity of this compound may be involved. This hypothesis is supported in part by the present results concerning G-CSF. We further speculated that elevated G-CSF concentrations in inflammatory states may produce the associated neutrophilia. The maintenance of neutrophil numbers seen in active SS and BD is an important feature in response to inflammatory stimuli. Neutrophil chemotaxis has been found to be enhanced, and this has been attributed to the increased level of a chemoattractant in the serum.
Both BD and SS yield similar laboratory findings, but the clinical course of SS is different from that of BD. In SS, most symptoms appear at the same time, while 1 or more symptoms of BD appear in the acute phase. After the initial symptoms appear, it takes several years for other symptoms to occur in BD, which is a chronic inflammatory disease with remissions and relapses.1 The patients with active SS had significantly higher serum G-CSF levels than the patients with active BD. This finding suggests that increased G-CSF serum levels play a prominent role in the worsening of SS, and at least some part in the worsening of BD. The elevated G-CSF levels in active BD may play a direct role in the disease process. Although we have documented quantitative G-CSF abnormalities in patients with active SS or BD, the difference in cause between SS and BD, including the role of G-CSF, remains unclear.
An inverse relationship between serum G-CSF level and active phase in our patients suggests a physiologic role of G-CSF in neutrophil homeostasis. The G-CSF prolongs survival of neutrophils while enhancing chemotaxis, phagocytosis, superoxide generation, and other metabolic functions.29 We evaluated the correlation between serum G-CSF level and neutrophil apoptosis in patients with active SS, those with active BD, and healthy controls by means of flow cytometry. Apoptosis, or programmed cell death, is a critical process in the regulation of cellular proliferation and differentiation. In normal hematopoiesis, apoptosis is thought to be involved in regulating the rate of committed cell production. It is responsible for the deletion of unwanted cells in different processes, including inflammation.30-32 Neutrophil apoptosis can be modulated by a variety of inflammatory mediators. Using culture medium supplemented with 10% FCS, we analyzed apoptotic neutrophil proportion. An accelerated rate of apoptosis was noted at 3, 6, and 18 hours of incubation in patients with active SS and active BD compared with healthy controls, and the percentage of apoptotic nuclei was significantly higher among active SS neutrophils at 18 hours compared with those of healthy controls. Similarly, the percentage of apoptotic neutrophils in active BD was higher than that in controls. This indicates that neutrophil apoptosis is accelerated in the active phase of disease. Furthermore, these data, based on incubation in FCS medium alone, suggest that apoptosis plays a large role in dramatically reducing neutrophilia in the active phase.
The inclusion of autologous serum led to a marked reduction in the rate of neutrophil apoptosis, and this was most prominent at 18 hours. Adding autologous serum to active SS or BD neutrophils was a more potent inhibitor of neutrophil apoptosis than FCS alone, suggesting a specific role for G-CSF in the regulation of neutrophil homeostasis. Apoptosis has been explained by a variety of neutrophil functional defects. The neutrophil apoptosis system seems to become less effective with progression of disease activity. This suggests that dysfunction associated with neutrophil apoptosis is an early, biologically relevant risk factor for active progression of the disease. The possible suppression of apoptosis in abnormal neutrophils by G-CSF requires further investigation. Furthermore, by better understanding the pathogenesis of this disorder, it may be possible to develop more effective treatment strategies for SS and BD through the induction of neutrophil apoptosis.
AUTHOR INFORMATION
Corresponding author and reprints: Tamihiro Kawakami, MD, Department of Dermatology, St Marianna University School of Medicine, 2-16-1 Sugao, Miyamae-ku, Kawasaki, Kanagawa, 216-8511, Japan (e-mail: tami{at}marianna-u.ac.jp).
Accepted for publication May 28, 2003.
This study was supported by grants from the Scientific Research Fund of the Ministry of Education, Science, Sports and Culture, Tokyo, Japan (Grant-in-Aid for Scientific Research No. 14570828) and the Basic Dermatological Research from Shiseido Co Ltd, Tokyo.
From the Department of Dermatology, St Marianna University School of Medicine, Kanagawa, Japan. The authors have no relevant financial interest in this article.
REFERENCES
1. Mizoguchi M, Chikakane K, Goh K, Asahina Y, Masuda K. Acute febrile neutrophilic dermatosis (Sweet's syndrome) in Behçet's disease. Br J Dermatol. 1987;116:727-734.
FULL TEXT
|
ISI
| PUBMED
2. Reuss-Borst MA, Muller CA, Waller HD. The possible role of G-CSF in the pathogenesis of Sweet's syndrome. Leuk Lymphoma. 1994;15:261-264.
ISI
| PUBMED
3. Reuss-Borst MA, Pawelec G, Saal JG, Horny HP, Müller CA, Waller HD. Sweet's syndrome associated with myelodysplasia: possible role of cytokines in the pathogenesis of the disease. Br J Haematol. 1993;84:356-358.
ISI
| PUBMED
4. Jain KK. Sweet's disease associated with granulocyte colony-stimulating factor. Cutis. 1996;57:107-110.
ISI
| PUBMED
5. Paydas S, Sahin B, Seyrek E, Soylu M, Gonlusen G. Sweet's syndrome associated with G-CSF. Br J Haematol. 1993;85:191-192.
ISI
| PUBMED
6. Fukutoku M, Shimizu S, Ogawa Y, et al. Sweet's syndrome during therapy with granulocyte colony-stimulating factor in a patient with aplastic anaemia. Br J Haematol. 1994;86:645-648.
ISI
| PUBMED
7. Prevost-Blank PL, Shwayder TA. Sweet's syndrome secondary to granulocyte colony-stimulating factor. J Am Acad Dermatol. 1996;35:995-997.
FULL TEXT
|
ISI
| PUBMED
8. Shimizu T, Yoshida I, Eguchi H, Takahashi K, Inada H, Kato H. Sweet syndrome in a child with aplastic anemia receiving recombinant granulocyte colony-stimulating factor. J Pediatr Hematol Oncol. 1996;18:282-284.
FULL TEXT
|
ISI
| PUBMED
9. Richard MA, Grob JJ, Laurans R, et al. Sweet's syndrome induced by granulocyte colony-stimulating factor in a woman with congenital neutropenia. J Am Acad Dermatol. 1996;35:629-631.
FULL TEXT
|
ISI
| PUBMED
10. Park JW, Mehrotra B, Barnett BO, Baron AD, Venook AP. The Sweet syndrome during therapy with granulocyte colony-stimulating factor. Ann Intern Med. 1992;116:996-998.
11. van Kamp H, van den Berg E, Timens W, Kraaijenbrink RA, Halie MR, Daenen SMGJ. Sweet's syndrome in myeloid malignancy: a report of two cases. Br J Haematol. 1994;86:415-417.
ISI
| PUBMED
12. von den Driesch P. Sweet's syndrome (acute febrile neutrophilic dermatosis). J Am Acad Dermatol. 1994;31:535-556.
ISI
| PUBMED
13. Takahama H, Itoh R, Inoue-Komatsu C, Furusawa S, Takahashi H, Mizoguchi M. Granulocyte colony-stimulating factor (G-CSF) and granulocyte macrophage colony-stimulating factor (GM-CSF) in Behçet's disease. J Dermatol. 1994;21:546-552.
PUBMED
14. Durand V, Renaudineau Y, Pers JO, Youinou P, Jamin C. Cross-linking of human FcgammaRIIIb induces the production of granulocyte colony-stimulating factor and granulocyte-macrophage colony-stimulating factor by polymorphonuclear neutrophils. J Immunol. 2001;167:3996-4007.
FREE FULL TEXT
15. Avalos BR, Gasson JC, Hedvat C, et al. Human granulocyte colony-stimulating factor: biologic activities and receptor characterization on hematopoietic cells and small cell lung cancer cell lines. Blood. 1990;75:851-857.
FREE FULL TEXT
16. Fye KH, Crowley E, Berger TG, LeBoit PE, Connolly MK. Celecoxib-induced Sweet's syndrome. J Am Acad Dermatol. 2001;45:300-302.
FULL TEXT
|
ISI
| PUBMED
17. Philpott NJ, Prue RL, Marsh JCW, Gordon-Smith EC, Gibson FM. G-CSF-mobilized CD34+ peripheral blood stem cells are significantly less apoptotic than unstimulated peripheral blood CD34+ cells: role of G-CSF as survival factor. Br J Haematol. 1997;97:146-152.
FULL TEXT
|
ISI
| PUBMED
18. Malone JC, Slone SP, Wills-Frank LA, et al. Vascular inflammation (vasculitis) in Sweet syndrome. Arch Dermatol. 2002;138:345-349.
FREE FULL TEXT
19. International Study Group for Behçet's Disease. Criteria for diagnosis of Behçet's disease. Lancet. 1990;335:1078-1080.
ISI
| PUBMED
20. Önder M, Gürer MA. The multiple faces of Behçet's disease and its aetiological factors. J Eur Acad Dermatol Venereol. 2001;15:126-136.
21. Gül A, Esin S, Dilsen N, Koniçe M, Wigzell H, Biberfeld P. Immunohistology of skin pathergy reaction in Behçet's disease. Br J Dermatol. 1995;132:901-907.
ISI
| PUBMED
22. Bloch-Michel E, Nussenblastt RB. International Uveitis Study Group recommendations for the evaluation of intraocular inflammatory disease. Am J Ophthalmol. 1987;103:234-235.
ISI
| PUBMED
23. Ritter MS, George MR, Serwatka LM, Elston CDM. Long-term suppression of chronic Sweet's syndrome with colchicine. J Am Acad Dermatol. 2002;47:323-324.
FULL TEXT
|
ISI
| PUBMED
24. Motojima H, Kobayashi T, Shimane M, Kamachi S, Fukushima M. Quantitative enzyme immunoassay for human granulocyte colony-stimulating factor (G-CSF). J Immunol Methods. 1989;118:187-192.
FULL TEXT
|
ISI
| PUBMED
25. Vecchiarelli A, Monari C, Baldelli F, et al. Beneficial effect of recombinant human granulocyte colony-stimulating factor on fungicidal activity of polymorphonuclear leukocytes from patients with AIDS. J Infect Dis. 1995;171:1448-1454.
ISI
| PUBMED
26. Migliorati G, Nicoletti I, D'adamio F, Spreca A, Pagliacci C, Riccardi C. Dexamethasone induces apoptosis in mouse natural killer cells and cytotoxic T lymphocytes. Immunology. 1994;81:21-26.
ISI
| PUBMED
27. Nicoletti I, Migliorati G, Pagliacci MC, Grignani F, Riccardi C. A rapid and simple method for measuring thymocyte apoptosis by propidium iodide staining and flow cytometry. J Immunol Methods. 1991;139:271-279.
28. Demetri GD, Griffin JD. Granulocyte colony-stimulating factor and its receptor. Blood. 1991;78:2791-2808.
FREE FULL TEXT
29. Asano S. Human granulocyte colony-stimulating factor: its basic aspects and clinical applications. Am J Pediatr Hematol Oncol. 1991;13:400-413.
ISI
| PUBMED
30. Cohen JJ. Apoptosis. Immunol Today. 1993;14:126-130.
ISI
| PUBMED
31. Savill J, Fadok V, Henson P, Haslett C. Phagocyte recognition of cells undergoing apoptosis. Immunol Today. 1993;14:131-136.
FULL TEXT
|
ISI
| PUBMED
32. Steller H. Mechanisms and genes of cellular suicide. Science. 1995;267:1445-1449.
FREE FULL TEXT
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
Sweet Syndrome Associated With Granulocyte Colony-Stimulating Factor
Bidyasar et al.
JCO 2008;26:4355-4356.
FULL TEXT
Karyotypic Analysis of Bone Marrow Cells in Pyodermic Lesions Associated With Myelodysplastic Syndrome
Hamada et al.
Arch Dermatol 2008;144:643-648.
ABSTRACT
| FULL TEXT
Drug-Induced Sweet's Syndrome
Thompson and Montarella
The Annals of Pharmacotherapy 2007;41:802-811.
ABSTRACT
| FULL TEXT
Histiocytoid Sweet Syndrome: A Dermal Infiltration of Immature Neutrophilic Granulocytes
Requena et al.
Arch Dermatol 2005;141:834-842.
ABSTRACT
| FULL TEXT
Sweet Syndrome: A Disease in Histologic Evolution?
Malone and Slone
Arch Dermatol 2005;141:893-895.
FULL TEXT
|
